ATE382358T1 - Verfahren und zusammensetzungen zum sauerstofftransport mit hoher sauerstoffaffinität - Google Patents

Verfahren und zusammensetzungen zum sauerstofftransport mit hoher sauerstoffaffinität

Info

Publication number
ATE382358T1
ATE382358T1 AT03705713T AT03705713T ATE382358T1 AT E382358 T1 ATE382358 T1 AT E382358T1 AT 03705713 T AT03705713 T AT 03705713T AT 03705713 T AT03705713 T AT 03705713T AT E382358 T1 ATE382358 T1 AT E382358T1
Authority
AT
Austria
Prior art keywords
compositions
oxygen
affinity
transport
present
Prior art date
Application number
AT03705713T
Other languages
German (de)
English (en)
Inventor
Robert Winslow
Kim Vandegriff
Original Assignee
Sangart Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangart Inc filed Critical Sangart Inc
Application granted granted Critical
Publication of ATE382358T1 publication Critical patent/ATE382358T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT03705713T 2002-01-11 2003-01-10 Verfahren und zusammensetzungen zum sauerstofftransport mit hoher sauerstoffaffinität ATE382358T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34774102P 2002-01-11 2002-01-11
US10/114,400 US20030153491A1 (en) 2002-01-11 2002-04-01 Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin

Publications (1)

Publication Number Publication Date
ATE382358T1 true ATE382358T1 (de) 2008-01-15

Family

ID=26812138

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03705713T ATE382358T1 (de) 2002-01-11 2003-01-10 Verfahren und zusammensetzungen zum sauerstofftransport mit hoher sauerstoffaffinität

Country Status (15)

Country Link
US (3) US20030153491A1 (enExample)
EP (1) EP1465643B1 (enExample)
JP (2) JP5149480B2 (enExample)
KR (1) KR100964604B1 (enExample)
CN (2) CN103203013A (enExample)
AT (1) ATE382358T1 (enExample)
AU (1) AU2003207504B2 (enExample)
BR (1) BR0306846A (enExample)
CA (1) CA2473662C (enExample)
DE (1) DE60318388T2 (enExample)
DK (1) DK1465643T3 (enExample)
ES (1) ES2299686T3 (enExample)
MX (1) MXPA04006733A (enExample)
PT (1) PT1465643E (enExample)
WO (1) WO2003059363A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
MXPA05006702A (es) * 2002-12-23 2005-09-30 Einstein Coll Med Hemoglobina modificada y metodos para hacer la misma.
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
CN100343304C (zh) * 2002-12-31 2007-10-17 尼克塔治疗亚拉巴马公司 水解稳定的马来酰亚胺封端的聚合物
US7790835B2 (en) 2003-12-03 2010-09-07 Nektar Therapeutics Method of preparing maleimide functionalized polymers
ES2347805T3 (es) * 2004-08-31 2010-11-04 Sangart, Inc. Metodos para aumentar la estabilidad hemodinamica usando composiciones que transportan oxigeno.
US8455437B2 (en) * 2005-02-04 2013-06-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method to predict and prevent oxygen-induced inflammatory tissue injury
CA2600927C (en) * 2005-03-07 2017-04-18 Sangart, Inc. Compositions and methods for delivering carbon monoxide (co) and nitric oxide (no) to tissue using heme proteins as carriers
WO2007050121A2 (en) * 2005-05-11 2007-05-03 Albert Einstein College Of Medicine Of Yeshiva University Site specific pegylated hemoglobin, method of preparing same, and uses thereof
US8071546B2 (en) * 2005-06-10 2011-12-06 La Jolla Bioengineering Institute Uses of pegylated albumin
US8741832B2 (en) * 2005-06-10 2014-06-03 Albert Einstein College Of Medicine Of Yeshiva University Pegylated albumin and uses thereof
DE602006013151D1 (de) * 2005-07-19 2010-05-06 Nektar Therapeutics Verfahren zur herstellung von polymermaleimiden
CA2653080C (en) 2006-05-22 2019-02-12 The Regents Of The University Of California Compositions and methods for the delivery of oxygen
US7504377B2 (en) * 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
CN101158676B (zh) * 2006-12-31 2011-12-14 重庆大学 一种评价血液及其代用品携氧、释氧功能的分析方法及装置
WO2009043031A2 (en) * 2007-09-27 2009-04-02 Children's Medical Center Corporation Microbubbles and methods for oxygen delivery
KR102210133B1 (ko) 2009-06-09 2021-02-01 프로롱 파마슈티컬스, 엘엘씨 헤모글로빈 조성물
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US9114109B2 (en) * 2009-06-16 2015-08-25 University of Pittsburgh—of the Commonwealth System of Higher Education Five-coordinate neuroglobin and use thereof as a blood substitute
US8273857B2 (en) * 2009-09-22 2012-09-25 Jen-Chang Hsia Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine
WO2011056799A1 (en) * 2009-11-05 2011-05-12 Sangart, Inc. Methods for preparing polyethylene glycol maleimide using n-(2-hydroxyethyl) maleimide as a starting material
EP2539715B1 (en) * 2010-02-25 2021-12-22 Sangart, Inc. Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios
US7989593B1 (en) 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
US8048856B1 (en) 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
EP2661275B1 (en) * 2011-01-07 2019-01-02 Poseida Therapeutics, Inc. Compositions and methods for delivery of high-affinity oxygen binding agents to tumors
US20120196270A1 (en) * 2011-02-02 2012-08-02 Sangart, Inc. Methods for preserving an organ for transplantation using a hemoglobin-carbon monoxide complex
US8889830B2 (en) 2011-03-01 2014-11-18 Chuo University Hemoglobin-albumin complex, and artificial plasma expander and artificial oxygen carrier containing the complex
US8084581B1 (en) 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US20130052232A1 (en) 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
WO2013070592A1 (en) * 2011-11-07 2013-05-16 The General Hospital Corporation Treatment of red blood cells
HK1207560A1 (en) * 2012-03-29 2016-02-05 Sangart, Inc. Diaspirin crosslinked pegylated hemoglobin
CN104411807B (zh) 2012-04-03 2018-10-02 桑加特公司 琥珀酰亚胺活化型硝酰化合物及其用于蛋白质硝酰化的使用方法
US10357450B2 (en) 2012-04-06 2019-07-23 Children's Medical Center Corporation Process for forming microbubbles with high oxygen content and uses thereof
WO2014107171A1 (en) 2013-01-07 2014-07-10 Omniox, Inc. Polymeric forms of h-nox proteins
CN105188761B (zh) * 2013-03-15 2020-05-15 桑加特公司 聚环氧烷戊酸酯血红蛋白缀合物
EP2968825A4 (en) 2013-03-15 2016-09-07 Childrens Medical Center Gas-filled stabilized particles and methods of use
HK1250137A1 (zh) 2015-03-17 2018-11-30 Omniox, Inc. 通过蛋白质介导的o2递送调节肿瘤免疫性
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
CN105497894B (zh) * 2015-12-21 2019-01-04 中国科学院深圳先进技术研究院 用于肿瘤光动力治疗的血红蛋白-光敏剂试剂及其应用
RU2018131359A (ru) 2016-02-16 2020-03-17 Омниокс, Инк. Модуляция гипоксии, ассоциированной с инсультом
EP3449004B1 (en) 2016-04-29 2021-02-24 Poseida Therapeutics, Inc. Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
EP3508214A4 (en) 2016-07-06 2020-05-13 Chuo University Therapeutic agent for ischemic diseases
ES2651717B1 (es) * 2016-07-26 2018-11-16 Lara OLLER DUQUE Solución acuosa cristaloide isotónica
US11147890B2 (en) 2017-02-28 2021-10-19 Children's Medical Center Corporation Stimuli-responsive particles encapsulating a gas and methods of use
CN112188865B (zh) * 2018-05-11 2024-08-27 斯佩克卓尼克斯股份有限公司 异常血氧合水平监测系统和方法及自监测氧合系统和方法
WO2020037052A1 (en) 2018-08-15 2020-02-20 Omniox, Inc. H-nox proteins for treating cardiovascular and pulmonary conditions
CN111499732B (zh) * 2020-04-22 2022-05-13 中国科学院过程工程研究所 一种基于双重化学修饰的血红蛋白氧载体及其制备方法和应用
WO2021261712A1 (en) * 2020-06-26 2021-12-30 Sunbio, Inc. Hemoglobin derivative co-conjugated with fatty acid-linked peg and alkoxy peg as a blood substitute
CN114617957B (zh) * 2022-03-10 2024-01-16 中国人民解放军军事科学院军事医学研究院 羟乙基淀粉血红蛋白偶联物及其制备方法与应用
WO2024112490A2 (en) * 2022-10-27 2024-05-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitrosyl-heme formulations for the treatment cardiovascular conditions, hemolysis, and the stabilization of cell-free heme molecules

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507146A (en) * 1968-02-09 1970-04-21 Webb James E Method and system for respiration analysis
US3956259A (en) * 1973-01-30 1976-05-11 Baxter Laboratories, Inc. Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate
US3925344A (en) * 1973-04-11 1975-12-09 Community Blood Council Plasma protein substitute
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2430898A1 (de) 1974-06-27 1976-01-08 Clevert Hans Dietmar Doppelkapillar-oxygenator
DE2449885C3 (de) * 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4061736A (en) * 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4001200A (en) * 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
CA1055932A (en) * 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
GB1578776A (en) * 1976-06-10 1980-11-12 Univ Illinois Hemoglobin liposome and method of making the same
JPS5329908A (en) * 1976-08-27 1978-03-20 Green Cross Corp:The Immobilized haptoglobin preparation
US4209300A (en) * 1978-09-25 1980-06-24 The United States Of America As Represented By The Department Of Health, Education And Welfare Hemoglobin-oxygen equilibrium curve analyzer
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5716815A (en) * 1980-07-02 1982-01-28 Ajinomoto Co Inc Oxygen transporting agent for artificial blood
US4401652A (en) * 1980-12-31 1983-08-30 Allied Corporation Process for the preparation of stroma-free hemoglobin solutions
JPS57206622A (en) * 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4532130A (en) * 1981-07-06 1985-07-30 Rush-Presbyterian-St. Luke's Medical Center Preparation of synthetic frythrocytes
DE3130770C2 (de) * 1981-08-04 1986-06-19 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Gewinnung von hepatitissicheren, sterilen, pyrogenfreien und stromafreien Hämoglobinlösungen
US4473496A (en) * 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
DE3144705C2 (de) * 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
CH650647A5 (de) * 1982-12-10 1985-08-15 Knorr Naehrmittel Ag Lagerfaehiges, zu einer dessert-mousse aufschlagbares produkt und verfahren zu dessen herstellung.
US4473494A (en) * 1983-05-04 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Preparation of stroma-free, non-heme protein-free hemoglobin
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
GB8328917D0 (en) * 1983-10-28 1983-11-30 Fisons Plc Blood substitute
US5281579A (en) * 1984-03-23 1994-01-25 Baxter International Inc. Purified virus-free hemoglobin solutions and method for making same
US4831012A (en) * 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
DE3412144A1 (de) * 1984-03-31 1985-10-10 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur herstellung hochgereinigter, stromafreier, hepatitissicherer human- und tierhaemoglobinloesungen
US4738952A (en) * 1984-04-27 1988-04-19 Synthetic Blood Corporation Substitute for human blood and a method of making the same
US4600531A (en) * 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4598064A (en) * 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5077036A (en) * 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
US5080885A (en) * 1986-01-14 1992-01-14 Alliance Pharmaceutical Corp. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4987154A (en) * 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
US5684050A (en) * 1986-01-24 1997-11-04 Hemagen/Pfc Stable emulsions of highly fluorinated organic compounds
US5194590A (en) * 1986-06-20 1993-03-16 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5464814A (en) * 1986-06-20 1995-11-07 Northfield Laboratories, Inc. Acellular red blood cell substitute
US4826811A (en) 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
DE3620873A1 (de) * 1986-06-21 1987-12-23 Rau Guenter Vorrichtung zur bestimmung des partialdruckes von in einem fluid geloesten gasen und gasgemischen
US4911929A (en) * 1986-08-29 1990-03-27 The United States Of America As Represented By The Secretary Of The Navy Blood substitute comprising liposome-encapsulated hemoglobin
DE3636590A1 (de) * 1986-10-28 1988-05-26 Braun Melsungen Ag Blutersatzmittel
US5084558A (en) * 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
CA1312009C (en) * 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
GB8710598D0 (en) * 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US4861867A (en) * 1988-02-03 1989-08-29 Baxter International, Inc. Purified hemoglobin solutions and method for making same
US4901727A (en) 1988-05-05 1990-02-20 The Boc Group, Inc. Micro-probe for gas sampling
US4900780A (en) * 1988-05-25 1990-02-13 Masonic Medical Research Laboratory Acellular resuscitative fluid
JPH07113599B2 (ja) 1988-07-29 1995-12-06 三菱石油株式会社 流動液体中の気泡含有量の動的定量装置
CA1338244C (en) * 1988-08-17 1996-04-09 Xiang-Fu Wu Purification of hemoglobin and methemoglobin by bioselective elution
US5061688A (en) * 1988-08-19 1991-10-29 Illinois Institute Of Technology Hemoglobin multiple emulsion
IL87707A (en) 1988-09-08 1994-06-24 Technion Inst For Research And Hemoglobin-based blood substitute substantially similar to human blood and method for preparation thereof
US5128452A (en) * 1989-04-19 1992-07-07 Baxter International Inc. Process for the production of crosslinked hemoglobin in the presence of sodium tripolyphosphate
US5599907A (en) * 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
NL8901174A (nl) 1989-05-10 1990-12-03 Het Hoofd Van De Afdeling Mili Hemoglobine-preparaat en gebruik daarvan.
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5312808A (en) * 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
US5650388A (en) * 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5234903A (en) 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5386014A (en) * 1989-11-22 1995-01-31 Enzon, Inc. Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute
US5041615A (en) * 1989-12-05 1991-08-20 Baxter International Inc. Preparation of bis(salicyl) diesters
US5239061A (en) * 1990-06-20 1993-08-24 Research Corporation Technologies, Inc. Modified human hemoglobin, blood substitutes containing the same, and vectors for expressing the modified hemoglobin
US5352773A (en) * 1990-08-06 1994-10-04 Baxter International Inc. Stable hemoglobin based composition and method to store same
US5248766A (en) * 1990-08-17 1993-09-28 Baxter International Inc. Oxirane-modified hemoglobin based composition
IT1244609B (it) 1990-09-14 1994-08-08 Instrumentation Lab Spa Procedimento ed apparecchiatura per la determinazione elettrochimica di specie gassose o volatili con particolare riferimento ad emogsanalizzatori.
US5114932A (en) * 1990-11-30 1992-05-19 Runge Thomas M Hyperosmolar oxyreplete hemosubstitute
US5234555A (en) * 1991-02-05 1993-08-10 Ibbott Jack Kenneth Method and apparatus for ionizing fluids utilizing a capacitive effect
CA2066374C (en) * 1991-04-19 2002-01-29 Paul E. Segall Solution for perfusing primates
US5295944A (en) * 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
US5250665A (en) * 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5349054A (en) * 1991-08-15 1994-09-20 Duke University Activated benzenepentacarboxylate-crosslinked low oxygen affinity hemoglobin
US5334705A (en) * 1991-08-15 1994-08-02 Duke University Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin
US5334706A (en) * 1992-01-30 1994-08-02 Baxter International Administration of low dose hemoglobin to increase perfusion
US5200323A (en) * 1992-01-31 1993-04-06 Mcgill University In vitro method to determine the safety of modified hemoglobin blood substitutes for human prior to clinical use
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5344393A (en) * 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US5264555A (en) 1992-07-14 1993-11-23 Enzon, Inc. Process for hemoglobin extraction and purification
US5628930A (en) * 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
CA2131455C (en) * 1993-03-16 1998-08-18 Diana Pliura Selective crosslinking of hemoglobin by oxidized, ring-opened saccharides
US5635538A (en) * 1993-03-16 1997-06-03 Alliance Pharmaceutical Corp. Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
US5612310A (en) * 1993-05-24 1997-03-18 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
WO1994028950A1 (en) * 1993-06-04 1994-12-22 Biotime, Inc. Plasma-like solution
US5407428A (en) * 1993-06-04 1995-04-18 Biotime, Inc. Solutions for use as plasma expanders and substitutes
US5578564A (en) * 1993-07-23 1996-11-26 Somatogen, Inc. Nickel-free hemoglobin and methods for producing such hemoglobin
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5545328A (en) * 1993-09-21 1996-08-13 Hemosol Inc. Purification of hemoglobin by displacement chromatography
CA2106612C (en) * 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US5585484A (en) * 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
US5525630A (en) * 1995-06-01 1996-06-11 Allos Therapeutics, Inc. Treatment for carbon monoxide poisoning
US5814601A (en) * 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
DE69831248T2 (de) * 1997-02-28 2006-04-13 The Regents Of The University Of California, Oakland Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen
US6269679B1 (en) * 1997-10-17 2001-08-07 The Regents Of The University Of California System and method to characterize gas transport properties
US5985825A (en) * 1998-02-28 1999-11-16 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
CA2233725A1 (en) * 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
WO2003059286A2 (en) * 2002-01-11 2003-07-24 Sangart, Inc. Methods and compositions for oxygen transport comprising modified hemoglobin in plasma
EP1472280A4 (en) * 2002-01-11 2005-09-21 Sangart Inc OXYGEN TRANSPORT METHODS AND COMPOSITIONS COMPRISING AN OXYGEN TRANSPORTER AND A CRYSTALLOID IN HYPERTONIC SOLUTION
MXPA05006702A (es) * 2002-12-23 2005-09-30 Einstein Coll Med Hemoglobina modificada y metodos para hacer la misma.

Also Published As

Publication number Publication date
DE60318388D1 (de) 2008-02-14
US6844317B2 (en) 2005-01-18
US20030162693A1 (en) 2003-08-28
MXPA04006733A (es) 2005-12-05
CA2473662C (en) 2009-12-22
KR20040081451A (ko) 2004-09-21
US6974795B2 (en) 2005-12-13
US20030153491A1 (en) 2003-08-14
US20050026816A1 (en) 2005-02-03
WO2003059363A1 (en) 2003-07-24
JP2010138197A (ja) 2010-06-24
AU2003207504B2 (en) 2007-05-24
DE60318388T2 (de) 2008-12-24
EP1465643A1 (en) 2004-10-13
JP5149480B2 (ja) 2013-02-20
CN1630527B (zh) 2013-04-24
KR100964604B1 (ko) 2010-06-21
JP2005515225A (ja) 2005-05-26
CN103203013A (zh) 2013-07-17
PT1465643E (pt) 2008-03-27
EP1465643A4 (en) 2004-10-20
AU2003207504A1 (en) 2003-07-30
BR0306846A (pt) 2004-12-07
CA2473662A1 (en) 2003-07-24
CN1630527A (zh) 2005-06-22
ES2299686T3 (es) 2008-06-01
EP1465643B1 (en) 2008-01-02
DK1465643T3 (da) 2008-05-13

Similar Documents

Publication Publication Date Title
ATE382358T1 (de) Verfahren und zusammensetzungen zum sauerstofftransport mit hoher sauerstoffaffinität
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
ATE477042T1 (de) Verkapselte aktive teilchen und verfahren für ihre herstellung und verwendung
SI1545587T1 (sl) Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede
ATE455861T1 (de) O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung
DE60325188D1 (de) Verfahren zur herstellung von sterilen, stabilisierten nanodispersionen
DE69831248D1 (de) Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
ATE502596T1 (de) Schmales zahnimplantat und zugeordnete teile
ATE464041T1 (de) Zusammensetzung zur hautaufhellung
ATE508646T1 (de) Proteinpulverzusammensetzung
IL165217A (en) Pesticidal pyridinecarboxamide derivatives, process for their preparation, pesticidal compositions comprising them and use thereof in the preparation of pesticidal compositions
PL1764378T3 (pl) Kompozycja katalizatorowa do polimeryzacji olefin, sposób polimeryzacji z zastosowaniem tej kompozycji, oraz sposób jej wytwarzania
DE60111732D1 (de) Verfahren zur herstellung von substituierten benzimidazolverbindungen
ATE367167T1 (de) Aufbereitung von aldesleukin zur pharmazeutischen verwendung
ATE273635T1 (de) Verfahren zum herstellen eines körperpflegemittels
ATE343605T1 (de) Zusammensetzungen zur herstellung von aminoplasterzeugnissen
ATE430559T1 (de) Verfahren zur herstellung von calciumzusammensetzungen im kontinuierlichen fliessbett
ATE506351T1 (de) Verfahren zur herstellung von 10,11-dihydro-10- oxo-5h-dibenzoäb,füazepin-5-carboxamid
ATE461617T1 (de) Verfahren und zusammensetzungen für die herstellung von mais mit erhöhter transformierbarkeit
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
ATE372687T1 (de) Verfahren zur verbesserung von proteinprodukten
DE50304242D1 (de) Verfahren zur herstellung von acylphosphinoxiden
ATE542436T1 (de) Nahrungsmittelsuspension, die beta-glucan enthält,und verfahren zu ihrer herstellung
DE50110561D1 (de) Non-metallocene, verfahren zur herstellung von diesen und deren verwendung zur polymerisation von olefinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1465643

Country of ref document: EP